Bank Julius Baer & Co. Ltd, Zurich Dynavax Technologies Corp Transaction History

Bank Julius Baer & Co. Ltd, Zurich

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$9.16 - $19.83 $4,653 - $10,073	-508 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$7.25 - $10.99 $58 - $87	8 Added 1.6%	508 $5,000
Q1 2021 May 10, 2021	SELL	$4.57 - $11.18 $4,903 - $11,996	-1,073 Reduced 68.21%	500 $5,000
Q4 2020 Feb 24, 2021	BUY	$3.73 - $5.6 $1,663 - $2,497	446 Added 39.57%	1,573 $7,000
Q4 2020 Feb 12, 2021	SELL	$3.73 - $5.6 $1,387 - $2,083	-372 Reduced 24.82%	1,127 $7,000
Q3 2020 Nov 10, 2020	SELL	$4.32 - $11.7 $17,284 - $46,811	-4,001 Reduced 72.75%	1,499 $6,000
Q2 2020 Aug 12, 2020	SELL	$2.94 - $9.1 $49 - $154	-17 Reduced 0.31%	5,500 $49,000
Q1 2020 May 13, 2020	BUY	$2.27 - $6.2 $12,523 - $34,205	5,517 New	5,517 $19,000

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.64B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.